The statistical analysis shows that there is a significant difference between resmetirom and placebo in NASH Biomarkers at 52 weeks which favors resmetirom group for CK-18/M30, Reverse T3 and favors placebo group for Adiponectin. Here, KRT18 is linked to metabolic dysfunction-associated steatohepatitis.